Fujirebio Europe NV - Strategic SWOT Analysis Review

Fujirebio Europe NV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

• Business description - A detailed description of the company’s operations and business divisions.
• Corporate strategy - The publisher's summarization of the company’s business strategy.
• SWOT analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history - Progression of key events associated with the company.
• Major products and services - A list of major products, services and brands of the company.
• Key competitors - A list of key competitors to the company.
• Key employees - A list of the key executives of the company.
• Executive biographies - A brief summary of the executives’ employment history.
• Key operational heads - A list of personnel heading key departments/functions.
• Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.

Highlights

Fujirebio Europe NV (Fujirebio Europe), a subsidiary of Fujirebio Inc, designs, develops and produces in vitro diagnostic (IVD) testing solutions and markets them worldwide. Its diagnostic products consist of Innotest products for ELISA; INNO-LIA products for autoimmune diseases; INNO-LiPA products for line probe assay; INNO-BIA products for bead-based multiparameter immunoassay, and Lumipulse products for chemiluminescent enzyme immunoassay (CLEIA) system, among others. The company products find application in the treatment of infectious diseases, cancer, genetic testing, fertility, thyroid, tissue typing, neurodegeneration, and bones. The company markets its products through its subsidiaries and distributors worldwide. Fujirebio Europe is headquartered in Gent, Belgium.

Fujirebio Europe NV Key Recent Developments

• Aug 08, 2023: GHIT Fund Welcomes Fujirebio as New Funding Partner
• Mar 31, 2023: Fujirebio further extends its fully automated blood-based biomarker portfolio with the fully automated Lumipulse G ApoE4 and Lumipulse G Pan-ApoE assays for research use only
• Mar 02, 2022: HU Group launches Lumipulse G pTau 181 Plasma assay for Alzheimer’s
• Mar 01, 2022: Fujirebio enters the field of fully automated blood-based Alzheimer’s disease biomarker testing with the release of the Lumipulse G pTau 181 plasma assay for research use only

Reasons to Buy

• Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
• Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
• Understand and respond to your competitors’ business structure and strategies with the publisher's detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
• Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.